ライフサイエンスコーパス: nonvalvular

1 4 patients with newly diagnosed (</=6 weeks) nonvalvular AF and >/=1 additional investigator-defined

2 0, 2014, we identified 655,000 patients with nonvalvular AF and a CHA2DS2-VASc score of >1 in the Nat

3 TS: This cohort study included patients with nonvalvular AF and a CHA2DS2-VASc score of 2 or more (ca

4 In patients with nonvalvular AF and a prior thromboembolic event despite

5 nducted at 59 hospitals of 707 patients with nonvalvular AF and at least 1 additional stroke risk fac

6 8,962 eligible individuals, 5,912 (66%) had nonvalvular AF and available eGFR data.

7 Patients diagnosed with nonvalvular AF and available estimated glomerular filtra

8 ith the Watchman device in 150 patients with nonvalvular AF and CHADS(2) (congestive heart failure, h

9 n Atrial Fibrillation), 14 264 patients with nonvalvular AF and creatinine clearance >/=30 mL/min wer

10 aban vs warfarin aged 50 years or older with nonvalvular AF and HIV.

11 for patients on hemodialysis with new-onset nonvalvular AF and matched subjects without arrhythmia.

12 Patients aged 65 years or older with nonvalvular AF and risk factors for stroke (CHADS score

13 ) with DOACs (95% apixaban) in patients with nonvalvular AF and with a history of cardioembolism, cli

14 ) with DOACs (95% apixaban) in patients with nonvalvular AF and with a history of cardioembolism, cli

15 and systemic embolic events in patients with nonvalvular AF as effectively as well-controlled, adjust

16 r 3.8 years of follow-up among patients with nonvalvular AF at elevated risk for stroke, percutaneous

17 In patients aged 65 years or older with nonvalvular AF at increased risk for stroke (CHADS score

18 In patients with nonvalvular AF at moderate to high risk of stroke, impai

19 ) for stroke risk reduction in patients with nonvalvular AF at multiple time points over a lifetime h

20 Patients with nonvalvular AF at risk for stroke treated with left atri

21 ministration, patients with newly diagnosed, nonvalvular AF between 2004 and 2012 were identified who

22 ministration, patients with newly diagnosed, nonvalvular AF between 2004 and 2015 followed by a PCI w

23 patients starting warfarin therapy owing to nonvalvular AF during the study period were monitored un

24 , we identified all patients discharged with nonvalvular AF from 1997 to 2011.

25 edictors of thromboembolism in patients with nonvalvular AF have been identified, but their mechanist

26 zed controlled trials enrolled patients with nonvalvular AF not treated with oral anticoagulants.

27 From nonvalvular AF patients (n = 154,259), we identified 11,

28 ve observational cohort study including 1722 nonvalvular AF patients from February 2008 to August 201

29 gistries were used to identify patients with nonvalvular AF patients with or without concomitant HF.

30 INNACLE FLX (Protection Against Embolism for Nonvalvular AF Patients: Investigational Device Evaluati

31 E FLX study (Protection Against Embolism for Nonvalvular AF Patients: Investigational Device Evaluati

32 we identified patients with newly diagnosed, nonvalvular AF seen within 90 days in an outpatient sett

33 -one studies comprising 12,451 patients with nonvalvular AF were included.

34 , the authors identified 9,769 patients with nonvalvular AF who started taking an oral anticoagulant

35 individual data from 2580 participants with nonvalvular AF who were prescribed aspirin in a multicen

36 This control cohort included patients with nonvalvular AF, recent ischemic stroke or transient isch

37 m a large global population of patients with nonvalvular AF, we sought to identify any differences in

38 se of the CHA2DS2-VASc stroke risk score for nonvalvular AF, with oral anticoagulation recommended fo

39 f DOAC availability on overall OAC rates for nonvalvular AF.

40 m, and cardiovascular death in patients with nonvalvular AF.

41 ention is no different in men and women with nonvalvular AF.

42 nts were eligible to be enrolled if they had nonvalvular AF; were indicated for oral anticoagulation

43 spirin and P2Y12 inhibitor) in patients with nonvalvular atrial fibrillation (AF) after percutaneous

44 on) trial demonstrated that in patients with nonvalvular atrial fibrillation (AF) and CHADS2 (congest

45 use of oral anticoagulation in patients with nonvalvular atrial fibrillation (AF) is a major issue th

46 cy of left atrial appendage (LAA) closure in nonvalvular atrial fibrillation (AF) patients ineligible

47 appendage occlusion (LAAO) in patients with nonvalvular atrial fibrillation (AF) remains uncertain.

48 arin for stroke prophylaxis in patients with nonvalvular atrial fibrillation (AF).

49 Among 91330 patients with nonvalvular atrial fibrillation (mean age, 74.7 years [S

50 Stented subjects with nonvalvular atrial fibrillation (n=2124) were randomized

51 Many patients with nonvalvular atrial fibrillation (NVAF) are at a high ris

52 lants (DOACs) are approved for patients with nonvalvular atrial fibrillation (NVAF) at high risk of b

53 reduces the risk of stroke in patients with nonvalvular atrial fibrillation (NVAF) but increases the

54 unction is associated with increased risk of nonvalvular atrial fibrillation (NVAF) in older adults w

55 verse events regarding stroke prevention for nonvalvular atrial fibrillation (NVAF) in the direct ora

56 The objective of this study is to describe nonvalvular atrial fibrillation (NVAF) incidence in Engl

57 f acute kidney injury (AKI) in patients with nonvalvular atrial fibrillation (NVAF) remains unknown.

58 stemic embolism, and cardiovascular death in nonvalvular atrial fibrillation (NVAF) requires continue

59 nsomnia, non-small cell lung cancer (NSCLC), nonvalvular atrial fibrillation (NVAF) stroke prevention

60 illation) trial that evaluated patients with nonvalvular atrial fibrillation (NVAF), left atrial appe

61 oembolic risk, particularly in patients with nonvalvular atrial fibrillation (NVAF).

62 efficacy and safety outcomes in Asians with nonvalvular atrial fibrillation (NVAF).

63 litus (DM) increases the risk of embolism in nonvalvular atrial fibrillation (NVAF). The association

64 al, Minneapolis, Minnesota) in patients with nonvalvular atrial fibrillation and absolute contraindic

65 Patients (n=707) with nonvalvular atrial fibrillation and at least 1 risk fact

66 Cs compared with VKAs to treat patients with nonvalvular atrial fibrillation and concomitant aspirin

67 t the analyses to those newly diagnosed with nonvalvular atrial fibrillation and naive-to-treatment,

68 was a man age 69 years with newly diagnosed nonvalvular atrial fibrillation and no contraindications

69 Of 11082 patients with nonvalvular atrial fibrillation and no known contraindic

70 ulation included 5386 patients with incident nonvalvular atrial fibrillation and type 2 diabetes mell

71 Patients with nonvalvular atrial fibrillation are at increased risk of

72 bigatran versus warfarin in the treatment of nonvalvular atrial fibrillation are lacking.

73 In patients with nonvalvular atrial fibrillation at high risk of cardioem

74 Patients with nonvalvular atrial fibrillation at increased risk of str

75 to dabigatran and warfarin in patients with nonvalvular atrial fibrillation at risk for stroke witho

76 as the first-choice therapy in patients with nonvalvular atrial fibrillation because these drugs have

77 harged from the hospital with a diagnosis of nonvalvular atrial fibrillation between 1997 and 2008.

78 ated dabigatran or warfarin for treatment of nonvalvular atrial fibrillation between October 2010 and

79 ool in reducing stroke risk in patients with nonvalvular atrial fibrillation but is underused.

80 with Watchman provides stroke prevention in nonvalvular atrial fibrillation comparable to warfarin,

81 y and effectiveness of stroke prevention for nonvalvular atrial fibrillation compared with the Watchm

82 mes) among older individuals with cancer and nonvalvular atrial fibrillation comparing DOACs and warf

83 ith VKA in anticoagulant-naive patients with nonvalvular atrial fibrillation during the early phase o

84 ischemic strokes and emboli in patients with nonvalvular atrial fibrillation from 4.5% to 1.4% per ye

85 Patients with nonvalvular atrial fibrillation have a 4- to 5-fold incr

86 Strategies in patients with nonvalvular atrial fibrillation have included anticoagul

87 Patients diagnosed with nonvalvular atrial fibrillation in a 4-hospital institut

88 dabigatran versus warfarin for treatment of nonvalvular atrial fibrillation in general practice sett

89 s with type 2 diabetes mellitus and incident nonvalvular atrial fibrillation in the period of May 1,

90 HMAN FLX LAA closure device in patients with nonvalvular atrial fibrillation in whom oral anticoagula

91 Nonvalvular atrial fibrillation is a major cause of thro

92 Nonvalvular atrial fibrillation is common in elderly pat

93 rect oral anticoagulants among patients with nonvalvular atrial fibrillation is not known.

94 Nonvalvular atrial fibrillation is the most common arrhy

95 ith dabigatran and warfarin in patients with nonvalvular atrial fibrillation is unknown.

96 Physicians managing patients with nonvalvular atrial fibrillation must consider the risks,

97 trospective cohort study of 1876 adults with nonvalvular atrial fibrillation or flutter seen in prima

98 We included 6022 nonvalvular atrial fibrillation patients from 912 center

99 Among nonvalvular atrial fibrillation patients treated with da

100 compare persistence rates in newly diagnosed nonvalvular atrial fibrillation patients treated with wa

101 d effectiveness outcomes among patients with nonvalvular atrial fibrillation receiving oral anticoagu

102 LAAC) for stroke prevention in patients with nonvalvular atrial fibrillation remain limited.

103 ibrillation, guidelines are silent regarding nonvalvular atrial fibrillation treatment among individu

104 A total of 52 patients with nonvalvular atrial fibrillation underwent LAAC with the

105 New users of anticoagulants with nonvalvular atrial fibrillation were followed until a st

106 tran prescriptions between 2010 and 2012 for nonvalvular atrial fibrillation were sampled (4863 total

107 e an alternative treatment for patients with nonvalvular atrial fibrillation who are less than optima

108 We randomly assigned 2124 participants with nonvalvular atrial fibrillation who had undergone PCI wi

109 tionwide cohort study included patients with nonvalvular atrial fibrillation who initiated dabigatran

110 igible participants were adult patients with nonvalvular atrial fibrillation who initiated oral antic

111 older) undergoing dialysis with a history of nonvalvular atrial fibrillation who met the CHADS-65 cri

112 cluded individuals diagnosed with cancer and nonvalvular atrial fibrillation who newly initiated DOAC

113 e database and including 91330 patients with nonvalvular atrial fibrillation who received at least 1

114 ility of SDD versus non-SDD in patients with nonvalvular atrial fibrillation who underwent LAAC.

115 l, we randomly assigned 14,264 patients with nonvalvular atrial fibrillation who were at increased ri

116 ied 39,400 patients discharged with incident nonvalvular atrial fibrillation with 0 or 1 CHA2DS2-VASc

117 United States is indicated in patients with nonvalvular atrial fibrillation with acceptable anatomy

118 Of 13,559 adults with nonvalvular atrial fibrillation, 11,526 were studied, 43

119 r long-term anticoagulation in patients with nonvalvular atrial fibrillation, and document the lowest

120 Among patients with nonvalvular atrial fibrillation, anticoagulation that re

121 e-dummy study of rivaroxaban and warfarin in nonvalvular atrial fibrillation, baseline characteristic

122 n preventing stroke and systemic embolism in nonvalvular atrial fibrillation, but has not been evalua

123 ally reduces the risk for ischemic stroke in nonvalvular atrial fibrillation, but its use among ambul

124 be cost-effective for typical patients with nonvalvular atrial fibrillation, but may be cost-effecti

125 Among patients taking NOACs for nonvalvular atrial fibrillation, concurrent use of amiod

126 lants (DOAC) over warfarin to treat isolated nonvalvular atrial fibrillation, guidelines are silent r

127 oke risk prediction schemes in patients with nonvalvular atrial fibrillation, highlight the strengths

128 onist therapy for venous thromboembolism and nonvalvular atrial fibrillation, major bleeding events,

129 hed data of patients >/=18 years of age with nonvalvular atrial fibrillation, randomized to either VK

130 or stroke prevention in 18 113 patients with nonvalvular atrial fibrillation.

131 7%) had heart failure, and 2,786 (19.3%) had nonvalvular atrial fibrillation.

132 d antithrombotic agents in patients who have nonvalvular atrial fibrillation.

133 strokes in a cohort of 13,559 patients with nonvalvular atrial fibrillation.

134 n patients with mechanical cardiac valves or nonvalvular atrial fibrillation.

135 e initial management strategy for persistent nonvalvular atrial fibrillation.

136 on alternative to warfarin for patients with nonvalvular atrial fibrillation.

137 romboembolic risk reduction in patients with nonvalvular atrial fibrillation.

138 ulation to prevent embolic events related to nonvalvular atrial fibrillation.

139 e to anticoagulation in select patients with nonvalvular atrial fibrillation.

140 ation to reduce stroke risk in patients with nonvalvular atrial fibrillation.

141 he Amulet occluder (Abbott) in patients with nonvalvular atrial fibrillation.

142 r preventing DRT after LAAC in patients with nonvalvular atrial fibrillation.

143 rials comparing VKAs and NOACs (n=71 681) in nonvalvular atrial fibrillation.

144 dent than in the management of patients with nonvalvular atrial fibrillation.

145 and risk of major bleeding in patients with nonvalvular atrial fibrillation.

146 farin in stroke prevention for patients with nonvalvular atrial fibrillation.

147 farin for stroke prevention in patients with nonvalvular atrial fibrillation.

148 ly INR-stable warfarin-treated patients with nonvalvular atrial fibrillation.

149 eventing ischemic stroke among patients with nonvalvular atrial fibrillation.

150 uperior to warfarin for stroke prevention in nonvalvular atrial fibrillation.

151 oral anticoagulants or VKA in patients with nonvalvular atrial fibrillation.

152 pared with warfarin in elderly patients with nonvalvular atrial fibrillation.

153 icant thromboembolic events in patients with nonvalvular atrial fibrillation.

154 g in the 110-mg dose in 18 113 patients with nonvalvular atrial fibrillation.

155 with warfarin for patients at risk who have nonvalvular atrial fibrillation.

156 duced intracranial bleeding in patients with nonvalvular atrial fibrillation.

157 lable to manage stroke risk in patients with nonvalvular atrial fibrillation; however, the cost-effec

158 We identified 1 141 097 patients with nonvalvular atrial fibrillation; the mean (SD) age was 7

159 troke and systemic embolism in patients with nonvalvular atrial fibrillation; transcatheter aortic va

160 association of biomarker or dietary ALA with nonvalvular CHF subtype.

161 uccessful biphasic electric cardioversion of nonvalvular persistent AF.

162 t valve procedure, and 45 (11.8%) concurrent nonvalvular procedures.